Pieter Sonneveld

Pieter Sonneveld

UNVERIFIED PROFILE

Are you Pieter Sonneveld?   Register this Author

Register author
Pieter Sonneveld

Pieter Sonneveld

Publications by authors named "Pieter Sonneveld"

Are you Pieter Sonneveld?   Register this Author

100Publications

1942Reads

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

J Clin Oncol 2018 Jul 2;36(20):2035-2043. Epub 2018 Feb 2.

Meletios Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Katja Weisel, University Hospital of Tuebingen, Tuebingen, Germany; Niels W.C.J. van de Donk, VU Universiteit Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Karthik Ramasamy, Oxford University Hospital and NIHR BRC Blood Theme, Oxford; Matthew Streetly, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom; Barbara Gamberi, Arcispedale S. Maria Nuova, Reggio Emilia; Massimo Offidani, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona; Antonio Ardizzoia, Oncology Department, ASST Lecco, Lecco, Italy; Frank Bridoux, University Hospital and University of Poitiers, Poitiers, France; Javier de la Rubia, Hematology Service University Hospital Doctor Peset and Universidad Católica de Valencia "San Vicente Mártir," Valencia; Maria-Victoria Mateos, Instituto de Investigación Biomédica de Salamanca and University of Salamanca, Salamanca, Spain; Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, and Pamela Bacon, Celgene International, Boudry, Switzerland; and Yan Li, Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ.

View Article
July 2018

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects.

Nat Commun 2018 07 27;9(1):2943. Epub 2018 Jul 27.

Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands.

View Article
July 2018

Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.

Pharmacogenomics 2018 02 15;19(3):213-226. Epub 2018 Jan 15.

Erasmus School of Health Policy & Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

View Article
February 2018

Management of multiple myeloma in the relapsed/refractory patient.

Authors:
Pieter Sonneveld

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):508-517

Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.

View Article
December 2017

MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands.

Cancer Epidemiol 2017 10 11;50(Pt A):137-140. Epub 2017 Sep 11.

Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address:

View Article
October 2017

Reply to X. Armoiry et al.

J Clin Oncol 2017 Sep 12;35(25):2976-2977. Epub 2017 Jul 12.

Chrissy H.Y. van Beurden-Tan, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Margreet G. Franken, Erasmus University Rotterdam, Rotterdam, Netherlands; Hedwig M. Blommestein, Erasmus University Rotterdam, Rotterdam, Netherlands; Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam, Netherlands; Hedwig M. Blommestein, Comprehensive Cancer Organisation, Utrecht, Netherlands; Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, Netherlands; and Pieter Sonneveld, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

View Article
September 2017

Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.

Haematologica 2017 08 20;102(8):e317-e320. Epub 2017 Apr 20.

Department of Oncology, KU Leuven - University of Leuven, LKI - Leuven Cancer Institute, Belgium

View Article
August 2017

Multiple myeloma.

Nat Rev Dis Primers 2017 Jul 20;3:17046. Epub 2017 Jul 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article
July 2017

Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.

J Clin Oncol 2017 Apr 27;35(12):1312-1319. Epub 2017 Feb 27.

Chrissy H.Y. van Beurden-Tan and Pieter Sonneveld, Erasmus MC Cancer Institute; Margreet G. Franken, Hedwig M. Blommestein, and Carin A. Uyl-de Groot, Erasmus University Rotterdam, Rotterdam; and Hedwig M. Blommestein and Carin A. Uyl-de Groot, Comprehensive Cancer Organisation, Utrecht, the Netherlands.

View Article
April 2017

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

Crit Rev Oncol Hematol 2017 Apr 14;112:153-170. Epub 2017 Feb 14.

Department of Haematology, University of Nantes Health Centre, Place Ricordeau, 44093, France.

View Article
April 2017

Should minimal residual disease negativity be the end point of myeloma therapy?

Authors:
Pieter Sonneveld

Blood Adv 2017 Mar 14;1(8):522-525. Epub 2017 Mar 14.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

View Article
March 2017

Daratumumab and Blood-Compatibility Testing.

N Engl J Med 2016 12 22;375(25):2497-8. Epub 2016 Dec 22.

View Article
December 2016

Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia.

Blood 2016 10 28;128(14):1854-1861. Epub 2016 Jun 28.

Department of Hematology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands.

View Article
October 2016

Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.

Clin Cancer Res 2016 Aug 4;22(16):4039-44. Epub 2016 Feb 4.

Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article
August 2016

Treatment of relapsed and refractory multiple myeloma.

Haematologica 2016 08;101(8):995

ErasmusMC Cancer Institute, The Netherlands.

View Article
August 2016

Prevalence of potential underlying aetiology of macrocytic anaemia in Dutch general practice.

BMC Fam Pract 2016 08 19;17(1):113. Epub 2016 Aug 19.

Department of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300, AK, Dordrecht, The Netherlands.

View Article
August 2016

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Aug;375(8):754-66

From the Department of Hematology, University of Turin, Turin, Italy (A.P.); the Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville (A.C.-K.); Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen (K.W.), and University Medical Center of the Johannes Gutenberg-University, Third Department of Medicine, Mainz (M.M.) - both in Germany; Winship Cancer Institute, Emory University, Atlanta (A.K.N.); the Department of Hematology and Stem Cell Transplantation, St. László Hospital, Semmelweis University, Budapest, Hungary (T.M.); Ankara University, Department of Hematology, Ankara, Turkey (M.B.); Clinical Department of Hematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic (I.S.); Irmandade Da Santa Casa De Misericordia De São Paulo, São Paulo (V.H.); University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain (M.V.M.); Weill Cornell Medical College, New York (T.M.M.); Janssen Research and Development, Spring House, PA (M.Q., X.Q., T.A.); Janssen Research and Development, Raritan, NJ (J.S., H.A.); Janssen Research and Development, Beerse, Belgium (W.D.); Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia (A.S.); and the Department of Hematology, Erasmus MC, Rotterdam, the Netherlands (P.S.).

View Article
August 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.

Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article
May 2016

Innovations in treatment and response evaluation in multiple myeloma.

Haematologica 2016 05;101(5):518-20

Erasmus MC Cancer Institute (EMC), Rotterdam, The Netherlands.

View Article
May 2016

Cytokine and viral load kinetics in human herpesvirus 8-associated multicentric Castleman's disease complicated by hemophagocytic lymphohistiocytosis.

Int J Hematol 2016 Apr 21;103(4):469-72. Epub 2015 Dec 21.

Section of Clinical Immunology, Department of Internal Medicine, Erasmus University MC, University Medical Center, Room D-419, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.

View Article
April 2016

Treatment of relapsed and refractory multiple myeloma.

Haematologica 2016 Apr;101(4):396-406

Erasmus MC Cancer Institute, Department of Hematology, Rm Na824, Rotterdam, the Netherlands.

View Article
April 2016

A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.

Eur J Haematol 2016 Feb 7;96(2):198-208. Epub 2015 May 7.

Department of Health Policy & Management/institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.

View Article
February 2016

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

Blood 2016 Feb 2;127(6):681-95. Epub 2015 Dec 2.

Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

View Article
February 2016

An update in treatment options for multiple myeloma in nontransplant eligible patients.

Expert Opin Pharmacother 2015 6;16(13):1945-57. Epub 2015 Aug 6.

Erasmus MC Cancer Institute (EMC), Department of Hematology , P.O. Box 2040, 3000 CA, Rotterdam , The Netherlands

View Article
November 2015

Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis.

PLoS One 2015 28;10(1):e0116966. Epub 2015 Jan 28.

Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; European Myeloma Network Board, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

View Article
October 2015

Multiple Myeloma--Better Drugs Ask for More Stringent Evaluations.

Authors:
Pieter Sonneveld

JAMA Oncol 2015 Sep;1(6):754-5

Department of Hematology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.

View Article
September 2015

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

J Clin Oncol 2015 Sep 3;33(26):2863-9. Epub 2015 Aug 3.

Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome, Rome; Elena Zamagni and Michele Cavo, Istituto di Ematologia Seragnoli, Università di Bologna, Bologna, Italy; Hervé Avet-Loiseau and Michel Attal, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse; Thierry Facon, Service des Maladies du Sang, Hôpital Claude Huriez, Centre Hospitalier Regionale et Universitaire Lille, Lille; Philippe Moreau, University Hospital Hotel-Dieu, Nantes, France; Henk M. Lokhorst, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC, Rotterdam, the Netherlands; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Laura Rosinol, Hospital Clínic, Institut Clínic d'Investigacions Biomèdiques Ausgust Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jésus San Miguel, Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas, IDISNA, Pamplona, Spain; Paul Richardson and Kenneth C. Anderson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; Shaji Kumar and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA; Robert Z. Orlowski, The University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX; Gareth Morgan, Myeloma Institutes for Research Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Brian G.M. Durie, Cedars-Sinai Comprehensive Canc

View Article
September 2015

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.

Expert Rev Hematol 2015 Aug 12;8(4):481-91. Epub 2015 Jun 12.

Myeloma Unit, Division of Haematology, University of Turin, Turin, Italy.

View Article
August 2015

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

J Clin Oncol 2015 Feb 20;33(6):657-64. Epub 2015 Jan 20.

Meletios A. Dimopoulos and Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Jens Hillengass and Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Saad Usmani, Carolinas Healthcare System, Charlotte, NC; Elena Zamagni and Michele Cavo, Bologna University School of Medicine, Bologna; Antonio Palumbo, S. Giovanni Battista Hospital, University of Turin, Turin, Italy; Suzanne Lentzsch, Columbia University College of Physicians and Surgeons, New York, NY; Faith E. Davies, Institute of Cancer Research, Sutton, United Kingdom; Noopur Raje, Massachusetts General Hospital Cancer Center; Kenneth Anderson, Dana-Farber Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Orhan Sezer, Memorial Sisli Hospital, Istanbul, Turkey; Sonja Zweegman, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, the Netherlands; Jatin Shah, MD Anderson Cancer Center, Houston, TX; Ashraf Badros, University of Maryland Medical Center, Baltimore, MD; Kazuyuki Shimizu, Tokai Central Hospital, Kakamigahara, Japan; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; Chor-Sang Chim, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region; Jian Hou, Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Artur Jurczyszyn, University Hospital, Krakow, Poland; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Bart Barlogie, University of Arkansas for Medical Sciences, Little Rock, AR; G. David Roodman, Indiana University School of Medicine, Indianapolis, IN; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; and Brian G.M. Durie, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA.

View Article
February 2015

Chemotherapy-induced peripheral neuropathies in hematological malignancies.

J Neurooncol 2015 Jan 19;121(2):229-37. Epub 2014 Oct 19.

Department of Neurology, Erasmus MC, 's Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands,

View Article
January 2015

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.

Leukemia 2014 Nov 15;28(11):2229-34. Epub 2014 Apr 15.

1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Hematology/Oncology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.

View Article
November 2014

Diagnosis and risk stratification in multiple myeloma.

Hematol Oncol Clin North Am 2014 Oct 22;28(5):791-813. Epub 2014 Jul 22.

Department of Hematology, Erasmus MC Cancer Institute, 's Gravendijkwal 230, Rotterdam 3015CE, The Netherlands. Electronic address:

View Article
October 2014

European perspective on multiple myeloma treatment strategies in 2014.

Oncologist 2014 Aug 25;19(8):829-44. Epub 2014 Jul 25.

Department of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria; Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands; Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; Department of Hematology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain; Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy; Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy; Haemato-Oncology Unit, Royal Marsden Hospital, Surrey, United Kingdom; Hematology Service, University Hospital La Fe, Valencia, Spain; Department of Hematology, University Hospital, Leuven, Belgium; Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany; Service d'Hématologie, Centre Hospitalier Universitaire, Lille, France; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; University Hospital, Nantes, France; Karolinska Institute, Stockholm, Sweden; Department of Hematology, Center Lillebaelt, University of Southern Denmark, Odense, Denmark; Clinica Universidad de Navarra, Centro Investigaciones Medicas Aplicada, Pamplona, Spain; Department of Hemato-oncology, University of Ostrava, Ostrava, Czech Republic; University of Giessen, Giessen, Germany.

View Article
August 2014

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

J Clin Oncol 2014 Jul 2;32(20):2173-80. Epub 2014 Jun 2.

Philippe Moreau, University Hospital Hôtel-Dieu; Jean-Luc Harousseau, Centre Rene Gauducheau, Nantes; Michel Attal, Centre Hospitalier Universitaire (CHU) Toulouse; Hervé Avet-Loiseau, CHU Rangueil, Toulouse; Gerald Marit, University Hospital of Bordeaux, Bordeaux; Cyrille Hulin, CHU Nancy, Nancy; Thierry Facon, Hopital Claude Huriez; Xavier Leleu, University Hospital of Lille, Lille; Denis Caillot, CHU Dijon, Dijon; Lotfi Benboubker, Centre Hospitalier Régional Universitaire Tours, Tours; Jean-Yves Mary, University Hospital Paris Saint-Louis, Paris, France; Michele Cavo, Annalisa Pezzi, and Elena Zamagni, Seràgnoli Institute of Hematology, Bologna; Antonio Palumbo, University of Torino, Torino; Maria Teresa Petrucci, Sapienza University of Rome, Rome; Francesca Patriarca, University Hospital, Udine, Italy; Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Bronno van der Holt, Daniel den Hoed Cancer Center at Erasmus Medical Center, Rotterdam; Henk Lokhorst, University Medical Center Utrecht, Utrecht, the Netherlands; Hartmut Goldschmidt, Universitätsklinikum Heidelberg; Kai Neben, University of Heidelberg, Heidelberg, Germany; Laura Rosinol and Joan Bladé, Hospital Clinic, Barcelona; Juan Jose Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jesus san Miguel, University of Salamanca; Norma Gutierrez, Hospital Universitario de Salamanca, Salamanca, Spain.

View Article
July 2014

Age and aging in blood disorders: multiple myeloma.

Haematologica 2014 Jul;99(7):1133-7

Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands

View Article
July 2014

Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.

Eur J Cancer 2014 Mar 31;50(5):1004-12. Epub 2013 Dec 31.

Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address:

View Article
March 2014

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

J Clin Oncol 2014 Feb 13;32(6):587-600. Epub 2014 Jan 13.

Antonio Palumbo and Alessandra Larocca, University of Torino, Torino; Michele Cavo, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Jesus F. San Miguel, University Hospital of Salamanca, Salamanca, Spain; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Gareth Morgan, Royal Marsden Hospital, London, United Kingdom; Ola Landgren, National Cancer Institute, Bethesda, MD; Roman Hajek, University of Ostrava School of Medicine and University Hospital Ostrava, Ostrava, Czech Republic; Hermann Einsele, University of Wurzburg, Wurzburg, Germany; Kenneth C. Anderson and Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Meletios A. Dimopoulos, University of Athens School of Medicine, Athens, Greece; Andrew Spencer, Alfred Hospital, Melbourne, Victoria, Australia; A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Kazuyuki Shimizu, Aichi Gakuin Hospital, Nagoya, Japan; Sagar Lonial, Emory University, Atlanta, GA; Pieter Sonneveld, Erasmus Medical Centre, Rotterdam, the Netherlands; Brian G.M. Durie, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; Philippe Moreau, University Hospital, Nantes, France; and Robert Z. Orlowski, MD Anderson Cancer Center, Houston, TX.

View Article
February 2014